Marc Wolff

Marc Wolff has more than sixteen years of experience in the life sciences industry in various global finance leadership and general management roles.

From October 2013 to June 2014, Mr. Wolff served as Chief Financial Officer of JHP Pharmaceuticals, a fully integrated specialty pharmaceutical company that acquires, develops, manufactures and sells branded and generic sterile products. He was responsible for all financial aspects of JHP, including HR and IT, and led the successful completion of the merger with Par Pharmaceutical, a deal valued $490 million.

Prior to joining JHP Pharmaceuticals, Mr. Wolff served as Chief Financial Officer of Research Pharmaceutical Services, Inc. (RPS) a leading provider of disruptive and innovative outsourcing clinical development solutions present in over 60 countries worldwide.
In this role, Mr. Wolff directed all financial, tax and treasury aspects of the business including accounting practices, budgeting, financial planning, financing, interface with the financial community, financial analysis, acquisitions and ventures, and monitoring financial, tax and treasury performance. He left RPS following the successful completion of the merger with PRA International.

Before joining Research Pharmaceutical Services, Mr. Wolff spent fifteen years with Catalent Pharma Solutions, a global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products, where he held various global finance leadership and general management roles.

Mr. Wolff joined Catalent in 1998 at RP Scherer France, a leader in Softgel Technologies, as Finance and HR director. He supported the facility’s $35 million expansion, leading to an FDA approval and further to the launch of two global pharmaceutical products for GSK. Following the acquisition of RP Scherer by Cardinal Health, he moved to Zug, Switzerland in 2001 and was promoted to Vice President Finance and IT Europe and General Manager of Cardinal Health Europe in Switzerland. In 2004, he relocated to Somerset, NJ to become global CFO for the Oral Technologies and the Packaging Services businesses and led a team of over 120 finance and accounting professionals. In 2007, Mr. Wolff supported the carve out of Cardinal Health’s Pharmaceutical Technologies and Services division, valued $3.3B by private equity group Blackstone, led the busin